0001213900-20-012311 S-8 4 20200514 20200514 20200514 CYREN Ltd. 0001084577 7372 000000000 L3 1231 S-8 33 333-238269 20878607 1 SAPIR ROAD 5TH FLOOR, BEIT AMPA P.O. BOX 4014 HERZLIYA L3 46140 7037603320 C/O CYREN INC. 1430 SPRING HILL ROAD, SUITE 330 MCLEAN VA 22102 COMMTOUCH SOFTWARE LTD 19990419 S-8 1 ea0121748-s8_cyrenltd.htm REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on May 14, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Cyren Ltd. (Exact name of registrant as specified in its charter) Israel Not Applicable (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 10 Ha-Menofim St., 5th Floor Herzliya, Israel 4672561 (Address of principal executive offices) (Zip Code) Cyren Ltd. 2016 Equity Incentive Plan, as amended and restated Cyren Ltd. 2016 Non-Employee Director Equity Incentive Plan, as amended and restated (Full Title of the Plans) J. Michael Myshrall Cyren Inc. 1430 Spring Hill Road, Suite 330, McLean, Virginia 22102 (703) 760-3320 (Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service) Copies of communications to: Laurie L. Green, Esq. Eric Spindel Adv. Adrian Daniels Greenberg Traurig, P.A. General Counsel and Yigal Arnon & Co. 401 East Las Olas Blvd. Corporate Secretary 1 Azrieli Center Suite 2000 Cyren Ltd. 132 Menachem Begin Road Fort Lauderdale, FL 33301 10 Ha-Menofim St., 5th Tel Aviv, Israel Floor +972-3-608-7856 Herzliya, Israel 4672561 +972𥑶636888 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non- accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of 搇arge accelerated filer, 揳ccelerated filer, 搒maller reporting company and 揺merging growth company in Rule 12b-2 of the Exchange Act. Large accelerated filer ? Accelerated filer ? Non-accelerated filer ? Smaller reporting company ? Emerging growth company ? If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ? CALCULATION OF REGISTRATION FEE Proposed maximum offering Proposed maximum Amount to be price per aggregate Amount of Title of securities to be registered registered (1) share (3) offering price (3) registration fee Ordinary Shares, par value ILS 0.15 per share 7,750,000 (2) $ 0.94 (3) $ 7,285,000 (3) $ 945.59 (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the 揝ecurities Act), this registration statement shall also cover any additional Ordinary Shares, par value ILS 0.15 per share (揙rdinary Shares), of Cyren Ltd., an Israeli corporation (the 揜egistrant), that become issuable under the terms of the Cyren Ltd. 2016 Equity Incentive Plan and the Cyren Ltd. 2016 Non-Employee Director Equity Incentive Plan, each as amended and restated (together, the 揚lans) by reason of any share split, share dividend, recapitalization or other similar transaction effected without the Registrant抯 receipt of consideration which results in an increase in the number of the outstanding Ordinary Shares of the Registrant. (2) Represents an additional 7,750,000 Ordinary Shares issuable under the Plans over and above the number of Ordinary Shares issuable under the Plans that were previously registered under the Securities Act. The number of shares to be registered under the respective plans are as follows: 2016 Equity Incentive Plan 7,000,000; and 2016 Non-Employee Director Equity Incentive Plan 750,000. (3) Calculated solely for the purpose of determining the registration fee pursuant to Rule 457(h) under the Securities Act on the basis of the average of the high and low prices of the Registrant抯 Ordinary Shares as quoted on the Nasdaq Capital Market on May 11, 2020. EXPLANATORY NOTE On July 30, 2019, the shareholders of the Registrant approved amendments to the Cyren Ltd. 2016 Equity Incentive Plan and the Cyren Ltd. 2016 Non-Employee Director Equity Incentive Plan, each as amended and restated (together, the 揚lans) to increase the number of Ordinary Shares available for issuance under the Plans by an aggregate of 7,750,000 Ordinary Shares. The number of shares to be registered under the respective plans are as follows: 2016 Equity Incentive Plan 7,000,000; and 2016 Non-Employee Director Equity Incentive Plan 750,000. Pursuant to General Instruction E of Form S-8, this Registration Statement registers the offer and sale of such additional Ordinary Shares. Such additional Ordinary Shares are of the same class of securities as the Ordinary Shares issuable under the Plans for which the currently effective registration statement on Form S-8 (File No. 333-223050) filed with the Securities and Exchange Commission (the 揅ommission) on February 15, 2018 (the 揚rior Registration Statement) was filed. As permitted by General Instruction E of Form S-8, the contents of the Prior Registration Statement, including any amendments thereto or filings incorporated therein, are incorporated by reference into this Registration Statement, except as amended hereby. PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT Item 3. Incorporation of Documents by Reference The following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the 揈xchange Act), other than information furnished pursuant to Items 2.02, 7.01 or 9.01 of Form 8-K, are incorporated herein by reference: Commission Filing Period Covered or Date of Filing Annual Report on Form 10-K Year ended December 31, 2019 Quarterly Report on Form 10-Q Quarter ended March 31, 2020 Current Reports on Form 8-K March 17, 2020 , March 19, 2020 and April 30, 2020 Description of Registrant抯 Ordinary Shares Form 8-A filed on June 25, 1999 and any amendment or report filed for the and Form F-1 (File No. purpose of updating such description 333-78531) filed on May 14, 1999, as amended, as updated by Exhibit 4.1 to the Annual Report on Form 10-K for the year ended December 31, 2019 All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (not including any information furnished under Items 2.02, 7.01 or 9.01 of Form 8-K, which information is not incorporated by reference herein) prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents. Any statement contained herein or in a document all or a portion of which is incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement. 1 Item 6. Indemnification of Directors and Officers Under the Israeli Companies Law 1999, as amended (the 揅ompanies Law), a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders. Under the Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator抯 award approved by a court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company抯 activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; reasonable litigation expenses, including attorneys fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, (1) provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding as a result of such investigation or proceeding; or (2) provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) a financial liability was imposed, but it was imposed with respect to an offense that does not require proof of criminal intent or in connection with a monetary sanction; reasonable litigation expenses, including attorneys fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent; payments which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law 1968, as amended (the 揝ecurities Law), and expenses the office holder incurred in connection with a proceeding under Chapters H'3, H'4 or I'1 of the Securities Law, including reasonable litigation expenses, including attorney's fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law; and expenses incurred by the office holder in connection with a proceeding under Chapter G'1 of the Restrictive Trade Law 1988 (the 揜estrictive Trade Law), including reasonable litigation expenses, including attorney's fees. Under the Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company抯 articles of association: a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; 2 a financial liability imposed on the office holder in favor of a third party; a payment which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Securities Law and expenses that the office holder incurred in connection with a proceeding under Chapters H'3, H'4 or I'1 of the Securities Law, including reasonable litigation expenses, including attorney's fees, or in connection with Article D of Chapter Four of Part Nine of the Companies Law; and Expenses incurred by the office holder in connection with a proceeding under Chapter G'1, of the Restrictive Trade Law, including reasonable litigation expenses, including attorney's fees. Under the Companies Law, a company may not indemnify or insure an office holder against any of the following: a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; an act or omission committed with intent to derive illegal personal benefit; or a fine or forfeit levied against the office holder. Further, the Securities Law, prohibits companies from exempting or indemnifying in advance or entering into a contract to insure the liability of an office holder of the company for (A) financial sanctions pursuant to the provisions of Chapter H3 of the Securities Law; (B) administrative infringements pursuant to the provisions of Chapter H4 of the Securities Law or (C) infringements pursuant to the provisions of Chapter I1 of the Securities Law. Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the shareholders. The Company抯 amended and restated articles of association permit it to exculpate, indemnify and insure its office holders to the fullest extent permitted or to be permitted by the Israeli Companies Law. The Company has obtained directors and officers liability insurance for the benefit of its office holders and intends to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. Item 8. Exhibits Exhibit Number Description Method of Filing 4.1 Memorandum of Association. Incorporated by reference to Exhibit 3.1 to the Registrant抯 Registration Statement on Form F-1 (File No. 33378531) filed on June 03, 1999. 4.2 Amended and Restated Articles of Incorporated by reference to Association, as amended on July 30, Exhibit 3.1 to the Registrant抯 2019. Current Report on Form 8-K filed on August 02, 2019. 5.1 Opinion of Yigal Arnon & Co., Israeli counsel to the Registrant, as to the validity of the Ordinary Shares (including consent). Filed herewith. 10.1 Cyren Ltd. 2016 Equity Incentive Incorporated by reference to Plan, as amended and restated. Exhibit 10.1 to the Registrant抯 Current Report on Form 8-K filed on August 02, 2019. 10.2 Cyren Ltd. 2016 Non-Employee Incorporated by reference to Director Equity Incentive Plan, as Exhibit 10.2 to the Registrant抯 amended and restated. Current Report on Form 8-K filed on August 02, 2019. 23.1 Consent of Kost, Forer, Gabbay and Kasierer, a member of Ernst & Young Global. Filed herewith. 24.1 Powers of Attorney (included on signature pages hereof). Filed herewith. 3 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of McLean, Commonwealth of Virginia on May 14, 2020. CYREN LTD. By: /s/ Brett Jackson Name: Brett Jackson Title: Chief Executive Officer POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS that each person whose signature appears below hereby constitutes and appoints Brett Jackson and J. Michael Myshrall, and each of them severally, acting alone and without the other, his or her true and lawful attorneys-in-fact and agents, with full power to act separately and full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement and all additional registration statements pursuant to Rule 462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or either of them or his or her or their substitute or substitutes may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated: Signature Title Date /s/ Brett Jackson Chief Executive Officer and Director May 14, 2020 Brett Jackson (Principal Executive Officer) /s/ J. Michael Myshrall Chief Financial Officer May 14, 2020 J. Michael Myshrall (Principal Financial and Accounting Officer) /s/ Lior Samuelson Chairman of the Board May 14, 2020 Lior Samuelson /s/ Hila Karah Director May 14, 2020 Hila Karah /s/ Todd Thomson Director May 14, 2020 Todd Thomson /s/ James Hamilton Director May 14, 2020 James Hamilton /s/ David Earhart Director May 14, 2020 David Earhart /s/ John Becker Director May 14, 2020 John Becker /s/ Cary Davis Director May 14, 2020 Cary Davis /s/ Brian Chang Director May 14, 2020 Brian Chang /s/ Rajveer Kushwaha Director May 14, 2020 Rajveer Kushwaha /s/ Lauren Zletz Director May 14, 2020 Lauren Zletz 4 EX-5.1 2 ea0121748ex5-1_cyrenltd.htm OPINION OF YIGAL ARNON & CO., ISRAELI COUNSEL TO THE REGISTRANT, AS TO THE VALIDITY OF THE ORDINARY SHARES Exhibit 5.1 [[Image Removed]] Yigal Arnon Yuval Bargil Eyal Aichel Ortal Tali Har-Oz Sophy Litvin (1929-2014) Eliran Roy Masuri Zanzuri Niv Blacher Igal Lavi Dror Vigdor Furman Avi Anouchi Roey Sasson Tal Alon Maor Layani Amalia Meshi Eran Lempert Sivan Gilron Shir Eshkol Ohad Sarusi Areen Nashef Amnon Lorch Ofir Levy Dotan Moshe Medved Mor Ido Tal Slabbaert Hagai Shmueli Daniel Green Tomer Lior Sofer Nechemia David Chesterman Barry Hanital Bar-Nathan Nir Rodnizky Englman Noam Kolt Levenfeld Belinson Edan Regev Noam Shochat Natalie Stav Ben Hamo David H. Yoheved Michal Sagmon Noa Slavin Korenfeld Ido Zahavi Schapiro Novogroder Hila Rot Michael Moshe Pasker Guy Yarom Hagit Bavly Oren Roth Neta Goshen Horowitz Mazi Ohayon Ben Nachshon Orna Sasson Dror Varsano Chen Lanir Guy Fatal Nitzan Danielle Barak Tal Odelia Sidi Daphna Livneh Shani Lorch Fisher-Conforti Berkowicz Shiri Shaham Shira Lahat Tamar Gilboa Itamar Cohen Victoria Savu Inbar Rosenthal Doron Tamir Micki Adi Samuel Shai Derora Tropp Dan Shimon Daniel Shapira Rachel Cohen Margalit Hila Amiel Lital Gamniel Abarbanel Eran Zach Alona Toledano Yonatan Chaim Cohen Matan Zigel Niv Zecler Ido Chitman Elad Offek Whitefield Shine Shaham Avital Salzman Ofer Argov Aner Hefetz Yuval Shamir Moshe Lankry Michal Mor Aharon Topper David Osborne David Akrish Liat Nir Kamhi Daniel Siso Rotem Cohen Gil Oren Nir Rosner Pillersdorf Shira Teger Maytal Spivak Ronit Amir Assaf Mesica Lihi Rachel Avraham Schoen Yaniv Liron Katzenelson Lerman Omer Razin Orly Tsioni Hacohen Inbar Ravid Saar Elan Loshinsky Mordehai Guy Fuhrer Hakimian-Nahari Sophie Ariel Even Baicz Ezra Gross Shahar Uziely Blackston Noah Zivan Barak Platt David Roness Yehudit Biton Elad Josh Hauser Benjamin Eli Gitit Morgenstern Eitan Cohen Horef Greenbaum Ramot-Adler Ron Itai Guttel Yoran Gill Lee Maor Omri Schnaider Ashkenazi Dor Brown Asaf Eylon Nimrod Shiran Sofer Sara Haber Dror Kanarik Daniel Vromen Rinat Michael Carmel Sarig Gidon Weinstock Marcovici Guy Sagiv Adi Attar Nudler Artium Gorelik Of Counsel Adrian Shani Daniella Milner Yehonatan Maor Alev Roy Keidar Of Daniels Rapoport Amos Oseasohn Cohen Tamar Drori Counsel Yuval Lior Gelbard Guy Kortany David Vered Glaubach Shalheveth Keren Tal Ofir Paz Shmulevitz Yair Taitelbaum Paul H. Baris Jacob Ben Naftali Nir Goor Koren Tair Gilad (1934-2010) Chitrit Yael Hoefler Adi Daniel Cherbakovsky Lindenfeld Rami Kook Peter Sagi Schiff Dafna Shaham Ophir Dagan Gabi Priel Nira Kuritzky Sugarman Netanella Miriam Liad Regina Pevzner Eran Ilan Ben Sandler Treistman Friedmann Kalderon Boaz Fiel Daniel Roni Osborne Nataly Joeri Damboritz Damary Kreisberg Yulia Lazbin Shiran Simon Joshua Glitman Weintraub Lieberman Dani Ruth Loven Weissberg Yarom Romem Lareine Adam Spruch Khoury Nohar Hadar Shirley Youseri Nitzan Kahana Tel Aviv | May 14, 2020 Cyren Ltd. 10 Ha-Menofim St., 5th Floor Herzliya, Israel 4672561 Ladies and Gentlemen: Re: Cyren Ltd. Form S-8 We refer to the Registration Statement on Form S-8 (the 揜egistration Statement) to be filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the 揝ecurities Act), on behalf of Cyren Ltd., a company organized under the laws of the State of Israel (the 揅ompany), for the purpose of registering under the Securities Act 7,750,000 of the Company抯 Ordinary Shares, nominal value NIS 0.15 per share (the 揝hares), available for issuance under the Cyren Ltd. 2016 Non-Employee Director Equity Incentive Plan and the Cyren Ltd. 2016 Equity Incentive Plan (together, the 揚lans). In rendering an opinion on the matters hereinafter set forth, we have assumed the authenticity of all original documents submitted to us as certified, conformed or photographic copies thereof, the genuineness of all signatures and the due authenticity of all persons executing such documents. We have assumed the same to have been properly given and to be accurate, we have assumed the truth of all facts communicated to us by the Company, we have assumed that all consents, minutes and protocols of meetings of the Company抯 board of directors and shareholders meetings of the Company which have been provided to us are true, accurate and have been properly prepared in accordance with the Company抯 incorporation documents and all applicable laws, and we have also assumed the compliance of any grant of Shares with the Company抯 compensation policy, as in effect from time to time. [[Image Removed]] As outside Israeli counsel to the Company, we have performed such investigations, and have examined such corporate records, certificates and other documents, and such questions of law, as we have considered necessary or appropriate for the purpose of our opinion. Upon the basis of such examination, we are of the opinion that, the Shares have been duly and validly authorized for issuance and, when issued in accordance with the applicable grant or option agreement, pursuant to the terms of the Plans and in accordance with the Registration Statement, the Shares will be legally and validly issued, fully paid and non-assessable. The above opinion is based on facts existing on the date hereof and of which we are aware. We express no opinion as to any laws other than the laws of the State of Israel as the same are in force on the date hereof and we have not, for purpose of giving this opinion, made any investigation of the laws of any other jurisdiction. This opinion is limited to the matters stated herein and no opinion is implied or may be inferred beyond the matters expressly stated. We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission thereunder. Very truly yours, /s/ Yigal Arnon & Co. Yigal Arnon & Co. 1 Azrieli Center, Tel Aviv, 6702101 | Phone: +972-3-6087777 | Fax: +972-3-6087724 31 Hillel Street, Jerusalem, 9458131 | Phone: +972-2-6239239 | Fax: +972-2-6239233 www.arnon.co.il | info@arnon.co.il -2- EX-23.1 3 ea0121748ex23-1_cyrenltd.htm CONSENT OF KOST, FORER, GABBAY AND KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statement on Form S-8 pertaining to the Cyren Ltd. 2016 Non-Employee Director Equity Incentive Plan and 2016 Equity Incentive Plan, each as amended and restated, of our report dated March 30, 2020, with respect to the consolidated financial statements of Cyren Ltd. included in its Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission. /s/ KOST, FORER, GABBAY & KASIERER KOST, FORER, GABBAY & KASIERER Tel Aviv, Israel A Member of Ernst & Young Global May 14, 2020